Clinical trials: Tumor Patients
Malignant Neoplasm
68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies
68Ga-JH04 is a novel radiotracer targeting fibroblast activation protein (FAP). In this study, we observed the safety, biodistribution, and radiation dosimetry of 68Ga-JH04 in patients with different types of cancer.
- Trial name
- NCT06438250
- Testing
- 68Ga-JH04
- Where
- China
- Volunteers
- 5 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Lung Cancer
Telephone Support Program for Lung Cancer Patients and Their Family Caregivers
The goal of this project is to examine the physical and psychological health benefits of a novel, telephone-delivered symptom management intervention for advanced lung cancer patients and their family caregivers.
- Trial name
- NCT01993550
- Testing
- Telephone counseling, Education
- Where
- 3 sites in United States
- Volunteers
- 262 people
- Sponsor
- Indiana University
Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of prexasertib in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor could not be detected or does not respond…
- Conditions
- Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm
- Trial name
- NCT02808650
- Testing
- Laboratory Biomarker Analysis, Pharmacokinetic (PK) study, Prexasertib
- Where
- 21 sites in United States
- Volunteers
- 30 people
- Sponsor
- Children's Oncology Group
Non-small Cell Lung Cancer
Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI
This is a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to evaluate the efficacy and safety of Toripalimab injection (JS001) or placebo combined with chemotherapy in Advanced Non-small Cell Lung…
- Trial name
- NCT03924050
- Testing
- TORIPALIMAB INJECTION(JS001 )
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Cutaneous Melanoma
5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results
The INTEGRATE Registry Study follows patients with cutaneous melanoma who have had the DecisionDx-Melanoma gene expression assay performed.
- Trial name
- INTEGRATE (NCT02355574)
- Where
- 3 sites in United States
- Volunteers
- 301 people
- Sponsor
- Castle Biosciences Incorporated
Acute Myelocytic Leukemia
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD123 in the treatment of Acute Myelocytic Leukemia.
- Trial name
- NCT03796390
- Testing
- CD123 CAR-T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation
Study CR-AIR-006 is a part of the ATIR clinical development plan and will provide control data for patients treated with ATIR in clinical studies (e.g. study CR-AIR-007).
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT02188290
- Where
- 9 sites in United States, Belgium and 4 more
- Volunteers
- 178 people
- Sponsor
- Kiadis Pharma
Renal Cell Carcinoma
Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy
Study PIM4973g is a multicenter, international, open-label Phase II trial. Participants with metastatic renal cell carcinoma who have progressed on or after VEGF targeted therapy will be randomized in 1:1 to two groups either to…
- Trial name
- NCT01442090
- Testing
- Everolimus, GDC-0980
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 85 people
- Sponsor
- Genentech, Inc.
Promyelocytic Leukemia, Adult Acute
RWE of 1st Line Treatment With ATO/ATRA for Adult APL
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of acute promyelocytic leukemia (APL) patients in the first line with arsenic trioxide and all…
- Trial name
- NCT04897490
- Testing
- Evaluation of first line treatment with ATO/ATRA outcome
- Where
- 6 sites in Argentina
- Volunteers
- 50 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
Small Cell Lung Cancer, Carcinoma, Small Cell
Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer
This proposed phase II trial will investigate weekly topotecan at a higher dose than was used in the previous trials in an attempt to achieve improved response rates and disease control without added toxicity.
- Trial name
- NCT00294190
- Testing
- Topotecan
- Where
- 13 sites in United States
- Volunteers
- 38 people
- Sponsor
- SCRI Development Innovations, LLC
Ovarian Cancer Recurrent
Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer
This is a feasibility single-center study to investigate the tolerability, toxicity, quality of life, morbidity, mortality of the HIPEC treatment following cytoreductive surgery for treatment of recurrent ovarian, peritoneal, and…
- Trial name
- NCT03717610
- Testing
- radical surgery with HIPEC
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Uppsala University Hospital
Small Cell Lung Cancer
Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer
This study plans to enroll 20 patients with recurrent small cell lung cancer. Patient-derived Organoid will be established, and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans.
- Trial name
- NCT06406660
- Testing
- Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib
The purpose of this study is assess the effects of the investigational drug dasatinib on participants who are in chronic phase Philadelphia chromosome chronic myeloid leukemia and who are either resistant to or intolerant of…
- Trial name
- NCT00101660
- Testing
- Dasatinib
- Where
- 85 sites in United States, Australia and 20 more
- Volunteers
- 387 people
- Sponsor
- Bristol-Myers Squibb
Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
The objective of this study is to determine the safety, tolerability, and anti-leukemic activity of S227928 as single agent and in combination with venetoclax, and to determine the recommended Phase 2 dose (RP2D) of this…
- Conditions
- Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Chronic Myelomonocytic Leukemia (CMML)
- Trial name
- NCT06563804
- Testing
- S227928, Venetoclax
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 13 people
- Sponsor
- Servier Bio-Innovation LLC
Multiple Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
Background: Carfilzomib is an experimental anti-cancer drug that has not yet been approved for treating multiple myeloma. Lenalidomide is a drug that may stop tumor growth and help the immune system kill cancer cells.
- Trial name
- NCT01402284
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Heart Failure
Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care
The transition of palliative care patients from inpatient to outpatient care is aimed to be improved through structured pharmaceutical discharge management by a trained pharmacist.
- Conditions
- Cancer, Heart Failure, COPD
- Trial name
- EntMedPall (NCT06648733)
- Testing
- Structured pharmaceutical discharge management
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital Muenster
Tumors
Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination
The study is designed to see if a course of injections containing the NY-ESO-1 protein (a tumor antigen, marker expressed by tumors); in combination with an immune stimulant (adjuvant) Montanide, with or without resiquimod…
- Trial name
- NCT00821652
- Testing
- NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Nina Bhardwaj
Solid Tumours
A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours)
This study is open to adults with advanced or metastatic solid cancer, such as non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, esophageal squamous cell carcinoma, bladder cancer…
- Trial name
- NCT07744152
- Testing
- BI 3822971
- Where
- 11 sites in Belgium, China and 3 more
- Volunteers
- 137 people
- Sponsor
- Boehringer Ingelheim
TNBC - Triple-Negative Breast Cancer
Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer: Korean Nationwide Multicenter Study (Pembro-Real World)
The purpose of this study is to evaluate the treatment outcomes and safety of neoadjuvant therapy including pembrolizumab in real-world practice for patients with triple-negative breast cancer (TNBC) in a multi-center study in…
- Trial name
- NCT07828652
- Testing
- Medical record use research
- Volunteers
- 2,000 people
- Sponsor
- Yeon Hee Park
Breast Cancer
Anesthetic Effect on Immune Cell in Patients With Cancer
Anesthetics agents has an effect on immune response during the cancer surgery.This influence can regulatory to immune activity or cancer cell survival.
- Trial name
- NCT02758249
- Testing
- Sevoflurane, propofol
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Konkuk University Medical Center